New hope for tough breast cancers: testing combo after standard treatments fail
NCT ID NCT05530057
Summary
This study is testing whether adding a biosimilar version of trastuzumab (a targeted therapy) to the chemotherapy drug eribulin works better than eribulin alone for people with advanced HER2-positive breast cancer. It's for patients whose cancer has continued to grow despite having already received at least two prior HER2-targeted treatments. The main goal is to see if the combination can better control the cancer's growth and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.